Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017

  • ID: 4311851
  • Report
  • 69 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Hemispherx Biopharma Inc
  • Innate Pharma SA
  • Johnson & Johnson
  • Oncovir Inc
  • RMB-Research GmbH
  • MORE
Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017

Summary:

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 - Pipeline Review, H1 2017, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Respiratory, Immunology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Other Diseases which include indications Breast Cancer, Asthma, Autoimmune Disorders, Chronic Inflammation, Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Acute Inflammation, Atherosclerosis, Bladder Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Obstructive Pulmonary Disease (COPD), Colitis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Foot Ulcers, Ebolavirus Infections (Ebola Hemorrhagic Fever), Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Injury, Liver Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Peritoneal Cancer, Pressure Ulcers, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Venous Leg Ulcers (Crural ulcer), West Nile Virus Infections, Wounds and Zika Virus Infections.

Furthermore, this report also reviewsalso reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
  • The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Hemispherx Biopharma Inc
  • Innate Pharma SA
  • Johnson & Johnson
  • Oncovir Inc
  • RMB-Research GmbH
  • MORE
  1. Introduction
  2. Toll Like Receptor 3 (CD283 or TLR3) - Overview
  3. Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
  14. Hemispherx Biopharma Inc
  15. Innate Pharma SA
  16. Johnson & Johnson
  17. MultiCell Technologies Inc
  18. Oncovir Inc
  19. RMB-Research GmbH
  20. Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
  21. Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. CNTO-3157 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. CU-CPT4a - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. Drugs to Activate TLR3 for Atherosclerosis - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. IPH-33 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. MCT-465 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. Oligonucleotide to Agonize TLR3 for Oncology - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. P-7 - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. PEP-0202 - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. Poly-ICLC - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. PrEP-001 - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. rintatolimod - Drug Profile
  66. Product Description
  67. Mechanism Of Action
  68. R&D Progress
  69. Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
  70. Product Description
  71. Mechanism Of Action
  72. R&D Progress
  73. Statmicoll - Drug Profile
  74. Product Description
  75. Mechanism Of Action
  76. R&D Progress
  77. Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
  78. Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
  79. Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
  80. Featured News & Press Releases
  81. May 31, 2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology
  82. May 15, 2017: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31,
  83. Mar 06, 2017: Hemispherx Biopharma Meets Ampligen Sales Milestone in the 1st Quarter of
  84. Feb 09, 2017: hVIVO announces data from two Phase IIa clinical studies to further profile PrEP Biopharm’s PrEP-001 as a potential prophylactic against the common cold
  85. Jan 26, 2017: Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen) for Sale to Early Access Program in Europe
  86. Jan 11, 2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
  87. Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME
  88. Oct 19, 2016: Hemispherx Biopharma Announces Completion of Ampligen Manufacturing Technology Transfer Milestone
  89. Aug 29, 2016: Hemispherx Biopharma to Present Data on the Activity of Ampligen Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA
  90. Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
  91. Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen
  92. Jul 25, 2016: Hemispherx Announces First Shipment of Rintatolimod (Ampligen) to Early Access Program in Europe
  93. Jun 14, 2016: hVIVO - Favourable results for PrEP Biopharms Flu Study
  94. Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology
  95. Jun 06, 2016: Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
  96. Appendix
  97. Methodology
  98. Coverage
  99. Secondary Research
  100. Primary Research
  101. Expert Panel Validation
  102. Contact Us
  103. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Indications, H1 2017 (Contd..2), H1
  6. Number of Products under Development by Companies, H1
  7. Products under Development by Companies, H1
  8. Products under Development by Companies, H1 2017 (Contd..1), H1
  9. Products under Development by Companies, H1 2017 (Contd..2), H1
  10. Number of Products under Investigation by Universities/Institutes, H1
  11. Products under Investigation by Universities/Institutes, H1
  12. Number of Products by Stage and Mechanism of Actions, H1
  13. Number of Products by Stage and Route of Administration, H1
  14. Number of Products by Stage and Molecule Type, H1
  15. Pipeline by Hemispherx Biopharma Inc, H1
  16. Pipeline by Innate Pharma SA, H1
  17. Pipeline by Johnson & Johnson, H1
  18. Pipeline by MultiCell Technologies Inc, H1
  19. Pipeline by Oncovir Inc, H1
  20. Pipeline by RMB-Research GmbH, H1
  21. Dormant Products, H1
  22. Dormant Products, H1 2017 (Contd..1), H1
  23. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Hemispherx Biopharma Inc
  • Innate Pharma SA
  • Johnson & Johnson
  • MultiCell Technologies Inc
  • Oncovir Inc
  • RMB-Research GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll